Clinical Trial: NCT06840548
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Philogen S.p.A. |
| Information Provided By: | Philogen S.p.A. |
| Last Update Posted: | 2026-01-13 |
Study Overview
Brief Summary
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
Official Title
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Intervention / Treatment
- Drug: [68Ga]Ga-OncoCAIX
Other Study ID Numbers
- PH-CAIXGA-02/24
- 2024-515607-19-00
Start Date (Actual)
2025-04-16
Primary Completion Date (Actual)
2025-11-28
Study Completion Date (Actual)
2025-11-28
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Philogen S.p.A. |
| Information Provided By: | Philogen S.p.A. |
| Last Update Posted: | 2026-01-13 |
Study Overview
Brief Summary
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
Official Title
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Intervention / Treatment
- Drug: [68Ga]Ga-OncoCAIX
Other Study ID Numbers
- PH-CAIXGA-02/24
- 2024-515607-19-00
Start Date (Actual)
2025-04-16
Primary Completion Date (Actual)
2025-11-28
Study Completion Date (Actual)
2025-11-28
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 1